Estrategias Combinadas en Inmunoterapia Traslacional
ITC
Centro Nacional de Investigaciones Oncológicas
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Centro Nacional de Investigaciones Oncológicas (9)
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Nature Communications, Vol. 12, Núm. 1
-
Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma
Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337
2020
-
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies
Annals of Oncology, Vol. 31, Núm. 9, pp. 1186-1197
2018
-
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity
Nature Communications, Vol. 9, Núm. 1
-
Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer
Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483
2015
-
Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice
Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478
2014
2013
-
Phosphorylated tubulin adaptor protein CRMP-2 as prognostic marker and candidate therapeutic target for NSCLC
International Journal of Cancer, Vol. 132, Núm. 9, pp. 1986-1995